The score’s strength comes from combining five different types of information rather than relying on a single laboratory result. Bilirubin, albumin, and prothrombin time or INR contribute laboratory evidence, while ascites and hepatic encephalopathy contribute clinical findings. Together, these inputs provide a broader picture of hepatic function and disease severity than any one measure alone.
Ascites and hepatic encephalopathy are important because the assessment is not limited to blood-test abnormalities. Their inclusion records clinically apparent complications of chronic liver disease alongside bilirubin, albumin, and coagulation results. This combined structure helps the resulting class reflect both measured laboratory changes and the patient’s clinical state when severity and prognosis are considered.
A Child-Pugh Score result should be interpreted as one part of a clinical assessment, not as a substitute for other evidence. Laboratory results, imaging, and clinical judgment can add information that the five score components do not capture. This broader review is especially important when clinicians use the score to support prognosis or decisions about treatment, procedures, or medications.
Clinicians first collect the five required findings: bilirubin, albumin, prothrombin time or INR, ascites, and hepatic encephalopathy. Each finding receives a point value corresponding to its severity, and the points are added to produce a total. That total is then used to assign class A, B, or C for the clinical assessment.
The A, B, and C classes organize the overall result into clinically meaningful severity groups. Clinicians use these groups to support estimates of prognosis and to inform treatment decisions, while recognizing that the class does not replace individualized judgment. The classification can also help frame discussions about the risks associated with procedures or medications in chronic liver disease.
The scoring system is useful when clinicians need a structured assessment of hepatic function and disease severity, particularly in chronic liver disease and cirrhosis. Its results can contribute to routine evaluation, prognosis, treatment planning, and consideration of procedure or medication risks. Because it summarizes selected findings, clinicians should combine it with imaging, additional laboratory results, and clinical judgment.